Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Tengjun Biotechnology Corp. (“Tengjun” or the “Company”) (OTC: TJBH) on behalf of Tengjun stockholders. Our investigation concerns whether Tengjun has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On September 5, 2023, Tengjun announced their previous financial statements on Form 10-K for “the fiscal year ended December 31, 2022, should no longer be relied upon due to accounting methodology errors in such financial statements and that the Board deems it advisable and in the best interests of the Company to restate the financial statements by amending its annual report on Form 10-K for the fiscal year ended December 31, 2022 as soon as reasonably practicable.”
On this news, the price of Tengjun’s American Depository Shares (“ADS”) fell $3.15 per ADS, or 17.64%, to close at $14.71 on September 5, 2023.
If you purchased or otherwise acquired Tengjun shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at firstname.lastname@example.org, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.